Navigation Links
Osteoporosis Drugs: right time to take-off

Millions of Indians are at risk of developing osteoporosis. While women are more likely to develop the disease, men are equal sufferers from it. It is estimated that at the age of 50, a woman has a 40 per cent chance of developing an osteoporotic fracture during her remaining lifetime. Drugs, which are used to treat osteoporosis, can be grouped into two classes. The first category comprises agents, which limit the rate of bone loss and are referred to as ‘‘anti-resorption drugs’’. The second group of drugs promotes bone formation and is referred to as ‘‘bone forming drugs’’.

// No single class of drugs is perceived to manage osteoporosis on a standalone basis. Hormone Replacement Therapy (HRT) and bisphosphonates are the most prescribed drugs. Calcium, vitamins and alfacalcidol preparations are also prescribed for prevention. The anti-osteoporosis market includes multinationals like Glaxo-Smithkline, Novartis, Infar and Wyeth Lederle. The Indian companies who have notched up a substantial market share are Cipla, Dr Reddy’s Laboratories and Elder Pharmaceuticals.

The Indian osteoporosis medications market presents great opportunity. Indian pharmaceutical companies need to increase awareness levels about the disease and it’s implications on both the physician as well as patient level. New compounds that rebuild bone mass and are associated with minimal side effects represent another area of opportunity. Currently, Selective Oestrogen Receptors Modulators (SERMs) such as Raloxifene and new generation bisphosphonates such as Risedronate have not been introduced in the Indian market. These drugs have a better efficacy and fewer side effects than the current therapies.

The osteoporosis medications market is viewed as a typical lifestyle related disease with high brand loyalty. Current lifestyle disease markets like cardiovascular and diabetes therapies are gradually getting saturated. The time is right for Indian pharmaceutical companies to focus on the osteoporosis medications market. br>


Related medicine news :

1. New treatment for Osteoporosis
2. Osteoporosis in men
3. Fluoride Found Effective in Osteoporosis
4. Mutation connected to Osteoporosis
5. Osteoporosis associated with Childhood Cancer
6. A treatment for Osteoporosis
7. Osteoporosis could be caused by irregular periods
8. Back exercises reduces Osteoporosis
9. Osteoporosis and kidney stones gene marker identified
10. The Answer To Prevent Osteoporosis
11. Blood Tests Can Help Detect Osteoporosis Early In Life
Post Your Comments:

(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: